Can a common arthritis drug ease MPS pain? new trial seeks answers.
NCT ID NCT03153319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adalimumab, a drug used for arthritis, can reduce pain and improve joint movement in people with MPS I, II, or VI. It includes children and adults aged 5 and older who have significant pain and limited joint motion. Participants receive either adalimumab or a placebo for 16 weeks, then all may receive the drug for up to a year. The goal is to see if the drug improves daily life and physical function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Lundquist Institute at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene Editing's lasting impact: a 10-Year safety watch
- Gene therapy watch: RGX-111 safety tracked in MPS i patients
- New registry aims to unlock secrets of rare childhood diseases
- Gene therapy breakthrough offers hope for boys with rare brain disease
- Massive french study aims to unlock secrets of rare MPS diseases
- Enzyme therapy shows promise for rare disease in china